# A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT01312389** · PHASE1,PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 3 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** OC-L/Montanide ISA 51 VG
- **BIOLOGICAL:** Ampligen
- **BIOLOGICAL:** Prevnar

## Key facts

- **NCT ID:** NCT01312389
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-05
- **Final completion:** 2012-08-17
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Did not meet criteria laid out in Phase 1 to continue to Phase 2
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01312389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01312389, "A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01312389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*